Johnson & Johnson (JNJ)

AI infrastructure is being funded with debt and stock sales while biotech companies applying AI are booking revenue, led by Tempus AI, Recursion and iShares Biotechnology

NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Keep focusing on the long term.

Value stocks are crushing growth stocks as investors sour on the artificial intelligence trade.

The stock market is looking overvalued, according to this indicator.

Some companies will perform pretty well regardless of whether or not interest rates rise.

They have both outperformed the broader equity market over the long run.

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

This ETF offers a smart middle ground for investors anxious about the AI trade but who don't want to sit on the sidelines.

AbbVie, J&J, and Medtronic remain reliable dividend plays in a rough market.

Selling surgical robots is not the largest source of Intuitive Surgical's revenue.

Johnson & Johnson announced results from three clinical analyses being presented during the Transcatheter Cardiovascular Therapeutics annual scientific symposium (TCT 2026) that report positive survival and patient outcomes data when Impella™ heart pumps are used to support a patient’s heart during and after high-risk percutaneous coronary intervention (HRPCI). Real-world and observational registry data from 1,379 HRPCI patients across hospitals in the U.S. and Europe show lower in-hospital cardiovascular mortality and lower 30- and 90-day mortality rates than those recently reported in CHIP-BCIS3. These contemporary findings from real-world U.S. and European experience with Impella-supported HRPCI provide important clinical context in contrast to the CHIP-BCIS3 study results.

Medtronic grew revenue by 14% in the first quarter of its fiscal 2027.

Consumers don't stop buying vital products during bear markets, which is why healthcare and consumer staples stocks are smart investments.

Johnson & Johnson's third-quarter 2026 earnings look terrible, until you dig into the story a little bit more.

Instead of trying to pick stocks like Warren Buffett, follow his advice and buy this S&P 500 ETF.

With just two days to go, these Dividend Kings with attractive yields could be just what you are looking for in October.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Johnson & Johnson (NYSE: JNJ) will hold an Enterprise Business Review for the investment community on Tuesday, December 8th, 2026. During the event, Company leaders will provide a detailed review of the Innovative Medicine and MedTech businesses, highlight how their pipelines are shaping the future of healthcare, and discuss the Company’s long-term strategy for delivering the next wave of growth and shareholder value.

Teradyne, Grail, Kratos Defense, FormFactor and Fabrinet have pulled back despite strong growth, setting up potential entry points in robotics, quantum and AI.

Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.

Intuitive Surgical posted Q3 margin impairments from a legal settlement and pricing changes, but revenue grew 21.5%, guidance firmed, and analysts and institutions remain bullish on ISRG.